Lamivudine treatment of chronic hepatitis B.

  • Dusheiko
  • Published 1998 in Reviews in medical virology


Several new nucleoside analogues have been developed which can inhibit hepatitis B replication by at least two logs. Lamivudine is the most widely studied of these new agents. Extensive phase II and III studies in patients with chronic hepatitis B have been completed. The sustained HBeAg seroconversion rate in patients who have received 100 mg lamivudine… (More)


Cite this paper

@article{Dusheiko1998LamivudineTO, title={Lamivudine treatment of chronic hepatitis B.}, author={Dusheiko}, journal={Reviews in medical virology}, year={1998}, volume={8 3}, pages={153-159} }